Total Payments
$217,274
2024 Payments
$7,738
Companies
14
Transactions
118
Payment Breakdown by Category
Consulting$101,086 (46.5%)
Travel$81,523 (37.5%)
Other$21,789 (10.0%)
Research$11,945 (5.5%)
Food & Beverage$931.17 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $101,086 | 61 | 46.5% |
| Travel and Lodging | $81,523 | 31 | 37.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,789 | 3 | 10.0% |
| Unspecified | $11,945 | 11 | 5.5% |
| Food and Beverage | $931.17 | 12 | 0.4% |
Payments by Type
General
$205,329
107 transactions
Research
$11,945
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $55,670 | 24 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $27,007 | 12 | $0 (2024) |
| ModernaTX, Inc. | $25,368 | 41 | $0 (2024) |
| GENZYME CORPORATION | $24,816 | 9 | $0 (2020) |
| Takeda Pharmaceutical Company, Limited | $22,809 | 4 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $22,538 | 6 | $0 (2018) |
| SANOFI US SERVICES INC. | $13,511 | 8 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $10,998 | 4 | $0 (2021) |
| Alexion Pharmaceuticals, Inc. | $7,510 | 4 | $0 (2017) |
| Biogen, Inc. | $2,574 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,738 | 14 | ModernaTX, Inc. ($5,913) |
| 2023 | $16,600 | 22 | ModernaTX, Inc. ($8,861) |
| 2022 | $14,070 | 13 | ModernaTX, Inc. ($9,133) |
| 2021 | $13,812 | 9 | Takeda Pharmaceuticals U.S.A., Inc. ($7,200) |
| 2020 | $10,727 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($7,780) |
| 2019 | $65,741 | 15 | Shire North American Group Inc ($32,510) |
| 2018 | $38,097 | 10 | SANOFI-AVENTIS U.S. LLC ($22,538) |
| 2017 | $50,491 | 32 | GENZYME CORPORATION ($19,919) |
All Payment Transactions
118 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 12/12/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $416.67 | General |
| 12/12/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| 12/12/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $208.33 | General |
| 10/18/2024 | Kyowa Kirin, Inc. | — | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| 08/01/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 08/01/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 07/05/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 07/05/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 02/29/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,462.50 | General |
| 02/29/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 02/29/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 02/29/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 01/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: GENETIC DISEASE | ||||||
| 12/14/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,057.50 | General |
| 12/14/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 09/27/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 09/21/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 08/09/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| 07/03/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 07/03/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 06/15/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,012.50 | General |
| 06/15/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $112.50 | General |
| 04/06/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 04/06/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA 3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency | ModernaTX, Inc. | $6,433 | 4 |
| A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA 3927 in Participants with Propionic Acidemia | ModernaTX, Inc. | $3,713 | 5 |
| A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA 3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency | Moderna TX, Inc. | $1,350 | 1 |
| An Extension Study for Participants Previously Enrolled in the mRNA-3927 Propionic Acidemia Phase 1 Paramount Study | ModernaTX, Inc. | $450.00 | 1 |
About Dr. Gregory Grabowski, M.D
Dr. Gregory Grabowski, M.D is a Clinical Genetics (M.D.) healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174547806.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Grabowski, M.D has received a total of $217,274 in payments from pharmaceutical and medical device companies, with $7,738 received in 2024. These payments were reported across 118 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($101,086).
Ad
Practice Information
- Specialty Clinical Genetics (M.D.)
- Location Cincinnati, OH
- Active Since 07/26/2006
- Last Updated 07/08/2007
- Taxonomy Code 207SG0201X
- Entity Type Individual
- NPI Number 1174547806
Products in Payments
- CEREZYME (Drug) $42,457
- VPRIV (Biological) $40,218
- Vpriv (Drug) $22,809
- CERDELGA (Drug) $10,511
- SOLIRIS (Drug) $7,510
- NO PRODUCT DISCUSSED (Drug) $4,950
- CEREZYME (Biological) $2,947
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Clinical Genetics (M.D.) Doctors in Cincinnati
Robert Hopkin, M.d, M.D
Clinical Genetics (M.D.) — Payments: $481,014
Clinical Genetics (M.D.) $481,014
Howard Saal, M.d, M.D
Clinical Genetics (M.D.) — Payments: $238,349
Clinical Genetics (M.D.) $238,349
Dr. Loren Pena, Md, Phd, MD, PHD
Clinical Genetics (M.D.) — Payments: $59,956
Clinical Genetics (M.D.) $59,956
Nancy Leslie, M.d, M.D
Clinical Genetics (M.D.) — Payments: $32,749
Clinical Genetics (M.D.) $32,749
Dr. Angela Sun, M.d, M.D
Clinical Genetics (M.D.) — Payments: $3,062
Clinical Genetics (M.D.) $3,062
Elizabeth Schorry, M.d, M.D
Clinical Genetics (M.D.) — Payments: $1,362
Clinical Genetics (M.D.) $1,362